SCM
ALNY icon

Soleus Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Soleus Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.95M Sell
33,050
-98,600
-75% -$29.7M 0.34% 55
2026
Q1 		$43.6M Buy
131,650
+61,650
+88% +$21M 1.76% 16
2025
Q4 		$27.8M Buy
70,000
+54,750
+359% +$24.2M 1.03% 27
2025
Q3 		$6.95M Sell
15,250
-91,500
-86% -$37.3M 0.35% 53
2025
Q2 		$34.8M Buy
+106,750
New +$29.5M 2.31% 13
2025
Q1 		– Sell
-76,800
Closed -$18.1M – 76
2024
Q4 		$18.1M Buy
76,800
+17,400
+29% +$4.58M 1.14% 27
2024
Q3 		$16.3M Sell
59,400
-12,300
-17% -$3.2M 1.27% 29
2024
Q2 		$17.4M Buy
+71,700
New +$11.3M 1.54% 25
2023
Q4 		– Sell
-3,900
Closed -$691K – 76
2023
Q3 		$691K Buy
+3,900
New +$744K 0.06% 84
2022
Q4 		– Sell
-27,000
Closed -$5.4M – 74
2022
Q3 		$5.4M Buy
27,000
+6,900
+34% +$1.32M 0.73% 40
2022
Q2 		$2.93M Buy
+20,100
New +$2.85M 0.46% 56

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's ALNY Position: Q2 2026 in Review

Soleus Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 75% in Q2 2026, selling an estimated $29.7M and leaving 33,050 shares worth $9.95M. The position accounts for 0.34% of the portfolio, ranked #55.

Soleus Capital Management first reported a position in ALNY in Q2 2022 and has held it in 11 quarters since. The position peaked at $43.6M in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Soleus Capital Management held 33,050 shares of Alnylam Pharmaceuticals worth $9.95M as of Q2 2026.
  • Soleus Capital Management sold 98,600 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $29.7M.
  • Alnylam Pharmaceuticals made up 0.34% of Soleus Capital Management's portfolio in Q2 2026, its #55 holding.
  • Soleus Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
  • Soleus Capital Management's Alnylam Pharmaceuticals position peaked at $43.6M in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.